NEW YORK (Reuters Health) - Ziprasidone, sold under the trade name Geodon, is well tolerated by patients and shows long-term efficacy as maintenance therapy for patients with schizophrenia who have not responded to other drugs, according to the results of a clinical trial published in the Journal of Clinical Psychiatry.
